ATG-101
Drug Detail
Contact
Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| Drug Name | ATG-101 |
| Trade Name | |
| Synonyms | ATG101|ATG 101|xirestomig |
| Drug Descriptions |
ATG-101 is a tetravalent bispecific antibody targeting PD-L1 (CD274) and TNFRSF9 (4-1BB), which activates TNFRSF9 (4-1BB) signaling and blocks PD-1/PD-L1 interaction, potentially leading to an enhanced antitumor immune response and inhibition of tumor growth (PMID: 38501978). |
| DrugClasses | Immune Checkpoint Inhibitor 150 PD-L1/PD-1 antibody 132 TNFRSF9 Antibody 36 |
| CAS Registry Number | 2756879-35-1 |
| NCIT ID | C190124 |
Filtering
- Case insensitive filtering will display rows if any text in any cell matches the filter term
- Use simple literal full or partial string matches
- Separate multiple filter terms with a space. Any order may be used (i. e. a b c and c b a are equivalent )
- Filtering will only apply to rows that are already loaded on the page. Filtering has no impact on query parameters.
- Use quotes to match on a longer phrase with spaces (i.e. "mtor c1483f")
Sorting
- Generally, the default sort order for tables is set to be first column ascending; however, specific tables may set a different default sort order.
- Click on any column header arrows to sort by that column
- Hold down the Shift key and click multiple columns to sort by more than one column. Be sure to set ascending or descending order for a given column before moving on to the next column.
| Therapy Name | Drugs | Efficacy Evidence | Clinical Trials |
|---|---|---|---|
| ATG-101 | ATG-101 | 0 | 1 |
CKB BOOST